Literature DB >> 11107448

Spontaneously occurring tumors of companion animals as models for human cancer.

D M Vail1, E G MacEwen.   

Abstract

Spontaneous tumors in companion animals (dog and cat) offer a unique opportunity as models for human cancer biology and translational cancer therapeutics. The relatively high incidence of some cancers, similar biologic behavior, large body size, comparable responses to cytotoxic agents, and shorter overall lifespan are the factors that contribute to the advantages of the companion animal model. The tumor types that offer the best comparative interest include lymphoma/leukemia, osteosarcoma, STS, melanoma, and mammary tumors. With the increase in new therapeutic agents (traditional chemotherapy, gene therapy, biologic agents, etc.), the companion animal model can provide useful populations to test new agents where efficacy and toxicity can be examined.

Entities:  

Mesh:

Year:  2000        PMID: 11107448     DOI: 10.3109/07357900009012210

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  169 in total

1.  Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Authors:  Shih-Hung Huang; Philip J Kozak; Jessica Kim; Georges Habineza-Ndikuyeze; Charles Meade; Anita Gaurnier-Hausser; Reema Patel; Erle Robertson; Nicola J Mason
Journal:  Virology       Date:  2012-03-08       Impact factor: 3.616

2.  Development and characterization of 5 canine B-cell lymphoma cell lines.

Authors:  Allison L Zwingenberger; William Vernau; Changying Shi; Wensheng Yan; Xinbin Chen; Ira K Gordon; Michael S Kent
Journal:  Leuk Res       Date:  2011-12-01       Impact factor: 3.156

Review 3.  A review of the association between osteosarcoma metastasis and protein translation.

Authors:  T S Osborne; C Khanna
Journal:  J Comp Pathol       Date:  2012-01-31       Impact factor: 1.311

Review 4.  Defining the Value of a Comparative Approach to Cancer Drug Development.

Authors:  Amy K LeBlanc; Christina N Mazcko; Chand Khanna
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

5.  Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.

Authors:  Sandra M Axiak-Bechtel; Senthil R Kumar; Kristin K Dank; Nicole A Clarkson; Kim A Selting; Jeffrey N Bryan; Thomas J Rosol; Jahna Espinosa; Charles J Decedue
Journal:  Invest New Drugs       Date:  2013-09-13       Impact factor: 3.850

6.  NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging.

Authors:  M V P Nadella; W C Kisseberth; K S Nadella; N K Thudi; D H Thamm; E A McNiel; A Yilmaz; K Boris-Lawrie; T J Rosol
Journal:  Vet Comp Oncol       Date:  2008-03       Impact factor: 2.613

7.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

8.  B-mode ultrasound examination of canine mammary gland neoplastic lesions of small size (diameter < 2 cm).

Authors:  Iacopo Vannozzi; Matteo Tesi; Marta Zangheri; Viola Maria Innocenti; Alessandra Rota; Simonetta Citi; Alessandro Poli
Journal:  Vet Res Commun       Date:  2018-03-14       Impact factor: 2.459

Review 9.  The challenges of assessing osteoarthritis and postoperative pain in dogs.

Authors:  Michele Sharkey
Journal:  AAPS J       Date:  2013-03-02       Impact factor: 4.009

10.  Copy number abnormalities in sporadic canine colorectal cancers.

Authors:  Jie Tang; Shoshona Le; Liang Sun; Xiuzhen Yan; Mucheng Zhang; Jennifer Macleod; Bruce Leroy; Nicole Northrup; Angela Ellis; Timothy J Yeatman; Yanchun Liang; Michael E Zwick; Shaying Zhao
Journal:  Genome Res       Date:  2010-01-19       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.